The Pharmaceutical Journal
Vol 269 No 7213 p273
31 August 2002

This article
Reprint
Photocopy

News summary

Benefit of long-acting risperidone

Treating patients with schizophrenia with long-acting risperidone (Risperdal Consta) can reduce the rate of hospital admissions, say researchers. An analysis of a one-year, open-label trial shows that the percentage of patients requiring admission to hospital fell from 38 per cent to 12 per cent after patients were switched from other antipsychotic drugs to long-acting risperidone.

Data were presented this week at the World Psychiatric Association congress in Japan.